- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05167643
H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study
Exploratory Study of HR-positive HER2-positive MBC Combined Treatment Plan
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Chunfang Hao, PhD
- Phone Number: 13602031629
- Email: haochf@163.com
Study Locations
-
-
-
Tianjin, China
- Recruiting
- Tianjin Cancer Hospital
-
Contact:
- Chunfang Hao, PhD
- Phone Number: 13602031629
- Email: haochf@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years old.
HR-positive and HER2-positive breast cancer diagnosed pathologically.
- ER positive and/or PR positive is defined as: the proportion of positively stained tumor cells in all tumor cells is ≥10% (reviewed and confirmed by the investigator at the test center);
- HER2 positive is defined as: standard immunohistochemistry (IHC) test for HER2 (3+), or HER2 (2+), FISH test is positive (reviewed and confirmed by the investigator at the test center).
- After H-based combined chemotherapy treatment has progressed (≤1 line), or the combined treatment is effective but not suitable for continued combined chemotherapy; or initially unsuitable for targeted combined chemotherapy for recurrent metastatic breast cancer or inoperable locally advanced breast cancer Breast cancer patients.
- Postmenopausal or premenopausal/perimenopausal female patients can be included in the group. Premenopausal or perimenopausal female patients must be willing to receive LHRHa treatment during the study period.
- According to the RECIST 1.1 standard, patients can have: a) measurable lesions; b) without measurable lesions, unmeasurable osteolytic or mixed (osteolytic + osteogenic) bone lesions. c) Unmeasurable lesions.
The main organs are functioning normally, that is, they meet the following standards:
The standard of routine blood examination should meet:
Hb≥80 g/L; ANC≥1.5×109 /L; PLT≥75×109 /L;
The biochemical inspection shall meet the following standards:
TBIL≤1.5×ULN (upper limit of normal value); ALT and AST≤2.5×ULN; if there is liver metastasis, ALT and AST≤5×ULN; Serum creatinine ≤1.5×ULN, creatinine clearance ≥50ml/min (based on Cockroft and Gault formula);
- Heart color Doppler ultrasound Left ventricular ejection fraction (LVEF) ≥50%.
Exclusion Criteria:
- Patients who have previously received CDK4/6 inhibitor drug therapy.
- T-DM1 treats patients.
- Female patients during pregnancy or lactation.
- Suffer from serious concomitant diseases, such as infectious diseases; there are many factors that affect the oral and absorption of drugs.
- Patients considered by the investigator to be unsuitable to participate in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Trastuzumab injection+Piperacillil tablets+Letrozole tablets
Trastuzumab injection:Once in 21 days IVD;Piperacillil tablets:125mg qd (d1-21) PO;Letrozole tablets:2.5mg
POqd;According to the current clinical guidelines combined with clinical practice, the treating physicians recommended the treatment plan to the subjects, and decided to enroll HR+/HER2+ advanced breast cancer patients treated with H combined with CDK4/6 inhibitor + AI±OFS into this study
|
According to the current clinical guidelines combined with clinical practice, the treating physicians recommended the treatment plan to the subjects, and decided to enroll HR+/HER2+ advanced breast cancer patients treated with H combined with CDK4/6 inhibitor + AI±OFS into this study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: Estimated 24 months
|
From enrollment to progression or death (for any reason)
|
Estimated 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: Estimated 24 months
|
Ratio of CR and PR in all subjects
|
Estimated 24 months
|
Disease Control Rate (DCR)
Time Frame: Estimated 24 months
|
Ratio of CR ,PR and SD in all subjects
|
Estimated 24 months
|
Overall survival (OS)
Time Frame: Estimated 36 months
|
From enrollment to death (for any reason)
|
Estimated 36 months
|
Security (CTCAE 5.0)
Time Frame: From informed consent through 28 days following treatment completion
|
Adverse events are described in terms of CTCAE 5.0
|
From informed consent through 28 days following treatment completion
|
Collaborators and Investigators
Investigators
- Principal Investigator: Chunfang Hao, PhD, Department of Breast Cancer Medical Oncology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Anastrozole
Other Study ID Numbers
- BC-CIH-H-RWS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced HR+ HER2 Negative Breast Carcinoma
-
Tianjin Medical University Cancer Institute and...Not yet recruitingAdvanced HR+ HER2 Negative Breast Carcinoma
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingHR-positive, HER2-negative Advanced Breast CancerChina
-
Henan Cancer HospitalRecruitingHR Positive HER2 Negative Advanced Breast CancerChina
-
Henan Cancer HospitalNot yet recruitingAdvanced Breast Cancer | Treatment | HR Low/HER2 Negative
-
Tianjin Medical University Cancer Institute and...RecruitingHR Positive HER2 Negative Advanced Breast CancerChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingHR-positive,HER2-negative in Advanced Breast CancerChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownHR-positive, HER2-negative and PIK3CA Mutation Advanced Breast CancerChina
-
Olema Pharmaceuticals, Inc.NovartisRecruitingAdvanced Breast Cancer | Metastatic Breast Cancer | HR-positive Breast Cancer | HER2-negative Breast CancerUnited States, Australia
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
Biocon Biologics UK LtdNot yet recruitingHR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
Clinical Trials on Enituzumab injection+Abesili tablets+Anastrozole tablets
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdJiangsu Alphamab Biopharmaceuticals Co., LtdRecruitingAdvanced Gastrointestinal TumorsChina
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
GlaxoSmithKlineTerminated
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruitingAdvanced Hepatocellular CarcinomaChina
-
Shenzhen Kangzhe Pharmaceutical Co., Ltd.UnknownHepatocellular Carcinoma
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruiting
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdActive, not recruitingUnresectable Hepatocellular CarcinomaChina
-
Tolmar Inc.RecruitingBreast CancerUnited States, Mexico, Brazil, Canada, Puerto Rico, Argentina
-
Tolmar Inc.Enrolling by invitationBreast CancerUnited States, Puerto Rico
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States